Health
Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial – News-Medical.Net
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and publi…
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
Tuberculosis is most common infectious disease cause of death in…
-
Noosa News17 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General18 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General15 hours agoIncreased police powers begin at Adelaide Oval Ashes Test following Bondi attacks
-
General23 hours agoDe-escalation skills, not guards, needed in Tasmanian hospitals, nurses’ union says